Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee sold 1,100 shares of common stock on September 3, 2026 at $11.1556 per share. According to the company’s sell-to-cover policy, this automatic sale was made solely to cover tax withholding from vested restricted stock units, and Banerjee now holds 140,947 shares directly.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan sold 61,888 shares of common stock on September 3, 2026 at a weighted average price of $11.1555 per share. The company states these automatic sales were made solely to cover tax withholding on vested restricted stock units, under a corporate sell-to-cover policy. Following the transaction, Aslan directly held 1,473,194 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. (ARTV) reported insider transactions by Chief Medical Officer Subhashis Banerjee on August 27, 2026. Banerjee exercised 5,306 stock options at $1.92 per share to acquire the same number of common shares, then sold 8,222 common shares at a weighted average of $12.0087 per share. The option exercise left 74,265 options outstanding and was carried out under a Rule 10b5-1 trading plan adopted on May 14, 2026.
Artiva Biotherapeutics, Inc. (ARTV) insider Subhashis Banerjee, an officer, filed a Rule 144 notice covering a potential sale of 7,818 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of approximately $92,017.86 for these shares as of the planned sale date of August 27, 2026.
The notice breaks out the shares as 5,183 shares to be acquired via exercise of stock options for cash on August 27, 2026 and 2,635 shares from restricted stock units vesting on May 15, 2026. It also reports that 429 shares of common stock were previously sold for $5,148.00 on August 18, 2026 under a Rule 10b5-1 trading plan.
Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee exercised employee stock options for 429 shares of common stock at an exercise price of $1.92 per share and immediately sold 429 shares of common stock at $12.00 per share on 2026-08-18. Following the option exercise, Banerjee held 79,571 stock options. The transactions occurred pursuant to a Rule 10b5-1 Plan adopted on May 14, 2026. The option grant vested 25% on April 8, 2026, with the remaining shares vesting monthly over the following 36 months.
Artiva Biotherapeutics, Inc. (ARTV) received a notice that officer Subhashis Banerjee intends to sell Artiva common stock under Rule 144. The planned sale involves 833 shares, expected to be sold on or about 08/18/2026, with the shares to be obtained through the exercise of stock options for cash. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed as the executing firm. Banerjee previously sold 7,037 shares of Artiva common stock on 05/19/2026. The notice states that additional shares will be received and sold upon option exercises over the next three months.
Artiva Biotherapeutics, Inc. received an amended Schedule 13G/A from a group of Venrock Healthcare-affiliated funds and individuals reporting their beneficial ownership of common stock. As of June 30, 2026, the reporting group collectively beneficially owned 2,043,596 shares of Artiva common stock. This represented 4.2% of the outstanding common stock, so the group now reports ownership of 5 percent or less of the class. All shares are held with shared voting and dispositive power through various Venrock Healthcare Capital Partners entities, with management entities and individuals Nimish Shah and Bong Y. Koh having shared authority as described.
Artiva Biotherapeutics, Inc. is the subject of an amended Schedule 13G/A filed by a group of investment entities affiliated with 5AM Ventures and individuals Andrew J. Schwab and Kush Parmar. As of June 30, 2026, the reporting entities collectively beneficially owned 2,353,304 shares of Artiva common stock, split between 1,171,250 shares held by 5AM Ventures VI, L.P. and 1,182,054 shares held by 5AM Opportunities II, L.P. The filing states that these holdings represent 4.8% of Artiva’s common stock for Schwab and Parmar and 2.4% for each fund-related reporting entity, calculated using 24,716,672 shares outstanding as of April 30, 2026 plus 23,871,526 shares issued in a public offering that closed on May 11, 2026. All voting and dispositive powers over these shares are shared among the relevant general partners and managing members, and each reporting person notes ownership of 5 percent or less of the class.
Artiva Biotherapeutics, Inc. has filed a shelf registration statement permitting the offer and sale, from time to time, of up to $400,000,000 of common stock, preferred stock, debt securities and warrants. This structure allows the company to issue securities in multiple tranches using prospectus supplements.
The filing also includes an at-the-market program under an amended and restated sales agreement with Leerink Partners LLC, through which Artiva may sell up to $100,000,000 of common stock on the Nasdaq Global Market, where its shares trade under the symbol ARTV and last closed at $11.59 on August 5, 2026. Net proceeds are intended for working capital and general corporate purposes, including research and development, administrative expenses and capital expenditures.